Your browser doesn't support javascript.
loading
Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.
Kumar, Awnish; Singh, Vishal Kumar; Tiwari, Rahul; Madhukar, Prasoon; Kumar, Shashi; Gautam, Vibhav; Engwerda, Christian; Sundar, Shyam; Kumar, Rajiv.
Afiliação
  • Kumar A; Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
  • Singh VK; Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
  • Tiwari R; Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
  • Madhukar P; Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
  • Rajneesh; Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
  • Kumar S; Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
  • Gautam V; Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
  • Engwerda C; Immunology and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
  • Sundar S; Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
  • Kumar R; Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Front Immunol ; 14: 1236952, 2023.
Article em En | MEDLINE | ID: mdl-37638047
ABSTRACT
Visceral leishmaniasis (VL) is a severe and often fatal form of leishmaniasis caused by Leishmania donovani in the Indian sub-continent. Post Kala-azar Dermal Leishmaniasis (PKDL) is a late cutaneous manifestation of VL, typically occurring after apparent cure of VL, but sometimes even without a prior history of VL in India. PKDL serves as a significant yet neglected reservoir of infection and plays a crucial role in the transmission of the disease, posing a serious threat to the VL elimination program in the Indian sub-continent. Therefore, the eradication of PKDL should be a priority within the current VL elimination program aimed at achieving a goal of less than 1 case per 10,000 in the population at the district or sub-district levels of VL endemic areas. To accomplish this, a comprehensive understanding of the pathogenesis of PKDL is essential, as well as developing strategies for disease management. This review provides an overview of the current status of diagnosis and treatment options for PKDL, highlighting our current knowledge of the immune responses underlying disease development and progression. Additionally, the review discusses the impact of PKDL on elimination programs and propose strategies to overcome this challenge and achieve the goal of elimination. By addressing the diagnostic and therapeutic gaps, optimizing surveillance and control measures, and implementing effective intervention strategies, it is possible to mitigate the burden of PKDL and facilitate the successful elimination of VL in the Indian sub-continent.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leishmania donovani / Leishmaniose Visceral Tipo de estudo: Diagnostic_studies Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Índia

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leishmania donovani / Leishmaniose Visceral Tipo de estudo: Diagnostic_studies Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Índia